abrdn Gold ETF Trust 3Q 2026 — 10-Q Summary

abrdn Gold ETF Trust (SGOL) reported a year-over-year decline in net assets due to smaller unrealized and realized gains on gold, despite an increase in share creations. Gold holdings rose to 1,716,361.6 ounces, and the gold price increased 3.73% to $4,176.30 per ounce. The Trust created 5,700,000 shares and redeemed 1,300,000 shares during the quarter, with expenses totaling $3,098,084.

Original reporting
Published Nov 6, 2026, 9:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 10:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
abrdn Gold ETF Trust 3Q 2026 — 10-Q Summary — source image
Decision brief

The 30-second read

$SGOLNeutralLow
01

Why it matters

For traders, the main value is understanding whether the trust’s share activity and holdings moved in line with gold price during the quarter; however, it is not a new forward-looking catalyst.

02

Market read

Quarterly disclosure can help validate gold-ETF flow and holdings trends, but it is unlikely to drive immediate price action absent new guidance or flow shocks.

03

What to watch

The summary does not quantify total net assets from operations or the magnitude of unrealized vs realized gain changes, limiting the ability to infer near-term flow or NAV pressure.

Relevance 4/10Novelty 4/10Timing: quarter-end 10-Q summary, published after the quarter closed

Background

The piece summarizes an SEC 10-Q for abrdn Gold ETF Trust, focusing on gold holdings, gold price performance during the quarter, share creation/redemption activity, and sponsor fees.

Company-level read

Ticker impact

$SGOLNeutralMedium confidence
Context

abrdn Gold ETF Trust 3Q 2026 10-Q summary reports gold holdings, share creations/redemptions, and sponsor fee for the quarter.

Expected impact

Likely limited near-term impact on SGOL price, as the disclosure is a quarterly filing summary rather than a new intraday catalyst.

Evidence & confidence

The article provides 3Q 2026 quarter-end figures (gold price up 3.73%, holdings up, creations exceed redemptions) but does not indicate a new policy, flow shock, or trading halt; it is informational for positioning rather than a fresh market-moving event.

Market effects

Provides incremental datapoints on gold ETF flow dynamics (creations vs redemptions) that can marginally inform gold-ETF sentiment.

None specific; US-listed gold ETF filing information is broadly relevant to US market participants.

None specific beyond reflecting gold price movement during the quarter.

Counterpoint

ETF NAV/operations changes may not translate into tradable signals because the filing is backward-looking and already reflects the quarter’s gold price path.

Key entities

  • abrdn Gold ETF Trust

    Gold-backed ETF trust; the article summarizes its 3Q 2026 operating metrics from a filed 10-Q.

  • SGOL

    Ticker referenced in the article as the trust’s SEC filing identifier.

Related articles

$AVGOMed

Why Broadcom Stock Could Double by 2030

Broadcom (AVGO) stock is down 12% YTD but grew Q3 revenue 86% YoY to $29.6B, with AI chip sales tripling. CEO Hock Tan expects AI revenue to double to $115B in 2027 and again to $230B in 2028. Concerns include data center delays and financing risks, but Anthropic's IPO raises $120B, easing worries. Analysts see potential for AVGO stock to double by 2030.

$BRK-BMed

Berkshire Hathaway Stock Jumps 14% in 2026 as Wall Street Downgrades

Berkshire Hathaway's Class B shares rose 13.4% in 2026, closing at $570 on November 20. Argus Research downgraded the stock to 'Hold' from 'Buy,' citing valuation concerns after it surpassed their $550 price target. The company's Q3 operating earnings declined 5.8% YoY to $12.71 billion, while net earnings fell 28% to $22.11 billion. Berkshire's performance contrasts with AI sector downturns, benefiting from its diversified portfolio.

$AVRMedAI 8/10

Anteris Reports Strong One-Year Results For DurAVR Heart Valve In High-Risk Aortic Stenosis Patients

Anteris Technologies (AVR) reported one-year data for its DurAVR heart valve, showing strong performance in high-risk aortic stenosis patients. Key metrics include 1% hospitalization for heart failure, 8.9 mmHg mean pressure gradient, and 96% of patients with mild or no symptoms post-treatment. The study involved 100 patients with complex conditions. Anteris stock closed at $4.99, up to $5.09 in after-hours trading.